Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mesothelioma, Malignant 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Metastatic Solid Tumors 1Metastatic NUT Carcinoma 1Melanoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cervical Adenocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bone Neoplasms 1Advanced NUT Carcinoma 1

Interventions

Trastuzumab 61Paclitaxel 57Cyclophosphamide 44pembrolizumab 35Fulvestrant 34Capecitabine 29Carboplatin 27Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 14durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Platinum × Clear all
NCT06351332 2026-05-22

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Dana-Farber Cancer Institute

Phase 1/2 Terminated
7 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡